Ms201781-0031- A Phase Ib Open-Label, Dose-Finding Trial To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Avelumab In Combination With M9241 (Nhs-Il12) In Subjects With Locally Advanced, Unresectable, Or Metastatic Solid Tumors
Posted Date: Jun 17, 2019
- Investigator: John Morris
- Specialties: Cancer, Oncology
- Type of Study: Drug
The goal of this study is to determine the safety, tolerability, and MTD of NHS-IL12 and avelumab when given in combination in subjects with metastatic or locally advanced solid tumors, and evaluate the confirmed best overall response (BOR) as assessed by the Investigator according to Response Evaluation Criteria in Solid Tumors
Criteria:
To Be Eligible: Age 18 Or Older, Must Have Metastatic Or Locally Advanced Solid Tumor In Which Standard Therapy Has Failed, Life Expectancy >12 Weeks
Keywords:
Metastatic Tumor, Cancer, Advanced
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com